MARCOMIGNI, Luca
MARCOMIGNI, Luca
DIPARTIMENTO DI MEDICINA CLINICA E SPERIMENTALE (attivo dal 01/01/1993 al 31/12/2013)
Alectinib's activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series
2016 Metro, Giulio; Lunardi, Gianluigi; Bennati, Chiara; Chiarini, Pietro; Sperduti, Isabella; Ricciuti, Biagio; Marcomigni, Luca; Costa, Cinzia; Crino', Lucio; Floridi, Piero; Gori, Stefania; Chiari, Rita
Correction: Repotrectinib’s Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung Cancer (Oncology and Therapy, (2024), 12, 1, (163-171), 10.1007/s40487-023-00251-6)
2024 Metro, G.; Gariazzo, E.; Costabile, S.; Baglivo, S.; Roila, F.; Colamartini, F.; Palumbo, B.; Chiarini, P.; Gori, S.; Conti, A.; Marcomigni, L.; Bellezza, G.; Lunardi, G.
Diagnosis and therapeutic management of parathyroid cancer, starting from the description of a clinical case
2020 Marasciulo, F.; Marcomigni, L.; Porreca, R.; Tomasello, L.; Roila, F.
Repotrectinib’s Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung Cancer
2023 Metro, G.; Gariazzo, E.; Costabile, S.; Baglivo, S.; Roila, F.; Colamartini, F.; Palumbo, B.; Chiarini, P.; Gori, S.; Conti, A.; Marcomigni, L.; Bellezza, G.; Lunardi, G.
Targeting EGFR and ALK in NSCLC: current evidence and future perspective
2016 Bennati, Chiara; Paglialunga, Luca; Ricciuti, Biagio; Metro, Giulio; Marcomigni, Luca; Gili, Alessio; Crino', Lucio
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Alectinib's activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series | 2016 | Metro, Giulio; Lunardi, Gianluigi; Bennati, Chiara; Chiarini, Pietro; Sperduti, Isabella; Ricciuti, Biagio; Marcomigni, Luca; Costa, Cinzia; Crino', Lucio; Floridi, Piero; Gori, Stefania; Chiari, Rita | |
| Correction: Repotrectinib’s Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung Cancer (Oncology and Therapy, (2024), 12, 1, (163-171), 10.1007/s40487-023-00251-6) | 2024 | Metro, G.; Gariazzo, E.; Costabile, S.; Baglivo, S.; Roila, F.; Colamartini, F.; Palumbo, B.; Chiarini, P.; Gori, S.; Conti, A.; Marcomigni, L.; Bellezza, G.; Lunardi, G. | |
| Diagnosis and therapeutic management of parathyroid cancer, starting from the description of a clinical case | 2020 | Marasciulo, F.; Marcomigni, L.; Porreca, R.; Tomasello, L.; Roila, F. | |
| Repotrectinib’s Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung Cancer | 2023 | Metro, G.; Gariazzo, E.; Costabile, S.; Baglivo, S.; Roila, F.; Colamartini, F.; Palumbo, B.; Chiarini, P.; Gori, S.; Conti, A.; Marcomigni, L.; Bellezza, G.; Lunardi, G. | |
| Targeting EGFR and ALK in NSCLC: current evidence and future perspective | 2016 | Bennati, Chiara; Paglialunga, Luca; Ricciuti, Biagio; Metro, Giulio; Marcomigni, Luca; Gili, Alessio; Crino', Lucio |